Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

Abstract Background Over the past years, EGFR tyrosine kinase inhibitors (TKI) revolutionized treatment response. 1st-generation (reversible) EGFR TKI and later the 2nd –generation irreversible EGFR TKI Afatinib were aimed to improve treatment response. Nevertheless, diverse resistance mechanisms de...

Full description

Bibliographic Details
Main Authors: Svenja Wagener-Ryczek, Carina Heydt, Juliane Süptitz, Sebastian Michels, Markus Falk, Christina Alidousty, Jana Fassunke, Michaela Angelika Ihle, Markus Tiemann, Lukas Heukamp, Jürgen Wolf, Reinhard Büttner, Sabine Merkelbach-Bruse
Format: Article
Language:English
Published: BMC 2020-05-01
Series:BMC Cancer
Subjects:
NSCLC
EGFR
TKI
Acquired resistance
Afatinib
Erlotinib
Online Access:http://link.springer.com/article/10.1186/s12885-020-06920-3

Internet

http://link.springer.com/article/10.1186/s12885-020-06920-3

Similar Items